Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Compound in dairy products targets diabetes
According to a researcher at Penn State, fatty acids commonly found in dairy products, known as conjugated linoleic acids (CLA), ave successfully treated diabetes in mice and have also shown promising results in human trials.
- New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain
Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone.
- New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain
Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone.
- New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain
Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone.
- New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain
Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone.
- New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain
Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone.
- New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging
A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
- New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging
A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
- New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging
A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
- New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging
A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
- New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging
A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
- New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging
A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
- New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin
Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs.
- New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin
Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs.
- New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin
Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs.
- New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin
Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs.
- New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin
Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs.
- Study Shows the Effectiveness of Oral Probiotic L. Rhamnosus GR-1™ and L. Reuteri RC-14™ In Treating Bacterial Vaginosis
Study published in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina.
- Study Shows the Effectiveness of Oral Probiotic L. Rhamnosus GR-1™ and L. Reuteri RC-14™ In Treating Bacterial Vaginosis
Study published in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina.
- Study Shows the Effectiveness of Oral Probiotic L. Rhamnosus GR-1™ and L. Reuteri RC-14™ In Treating Bacterial Vaginosis
Study published in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina.
- Study Shows the Effectiveness of Oral Probiotic L. Rhamnosus GR-1™ and L. Reuteri RC-14™ In Treating Bacterial Vaginosis
Study published in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina.
- Low vitamin E intake during pregnancy can lead to childhood asthma
Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five.
- Low vitamin E intake during pregnancy can lead to childhood asthma
Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five.
- Low vitamin E intake during pregnancy can lead to childhood asthma
Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five.
- Low vitamin E intake during pregnancy can lead to childhood asthma
Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five.
- Low vitamin E intake during pregnancy can lead to childhood asthma
Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five.
- Study Shows That Pine Tree Bark Reduces Diabetic Leg Ulcers
Study published in the July journal of Clinical and Applied Thrombosis/Homeostasis shows that Pycnogenol heals leg ulcers in patients who suffer from diabetic leg ulcerations.
- Study Shows That Pine Tree Bark Reduces Diabetic Leg Ulcers
Study published in the July journal of Clinical and Applied Thrombosis/Homeostasis shows that Pycnogenol heals leg ulcers in patients who suffer from diabetic leg ulcerations.
- Study Shows That Pine Tree Bark Reduces Diabetic Leg Ulcers
Study published in the July journal of Clinical and Applied Thrombosis/Homeostasis shows that Pycnogenol heals leg ulcers in patients who suffer from diabetic leg ulcerations.
- Study Shows That Pine Tree Bark Reduces Diabetic Leg Ulcers
Study published in the July journal of Clinical and Applied Thrombosis/Homeostasis shows that Pycnogenol heals leg ulcers in patients who suffer from diabetic leg ulcerations.
- Prenatal Vitamins May Reduce Risk of Brain Tumors in Children
Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors.
- Prenatal Vitamins May Reduce Risk of Brain Tumors in Children
Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors.
- Prenatal Vitamins May Reduce Risk of Brain Tumors in Children
Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors.
- Prenatal Vitamins May Reduce Risk of Brain Tumors in Children
Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors.
- Prenatal Vitamins May Reduce Risk of Brain Tumors in Children
Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors.
- Pine Tree Bark Reduces Diabetic Microangiopathy
Study published in the September edition of Angiology shows that supplementation with Pycnogenol significantly reduced diabetic microangiopathy (DM).
- Pine Tree Bark Reduces Diabetic Microangiopathy
Study published in the September edition of Angiology shows that supplementation with Pycnogenol significantly reduced diabetic microangiopathy (DM).
- Pine Tree Bark Reduces Diabetic Microangiopathy
Study published in the September edition of Angiology shows that supplementation with Pycnogenol significantly reduced diabetic microangiopathy (DM).
- Pine Tree Bark Reduces Diabetic Microangiopathy
Study published in the September edition of Angiology shows that supplementation with Pycnogenol significantly reduced diabetic microangiopathy (DM).
- Turmeric supplements show promise in treating arthritis
New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response.
- Turmeric supplements show promise in treating arthritis
New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response.
- Turmeric supplements show promise in treating arthritis
New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response.
- Turmeric supplements show promise in treating arthritis
New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response.
- Turmeric supplements show promise in treating arthritis
New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response.
- Turmeric supplements show promise in treating arthritis
New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- Higher level of certain fatty acid associated with lower dementia risk
Individuals who have higher levels of a fatty acid known as docosahexaenoic acid (DHA) in their blood may have a significantly lower risk of developing dementia and Alzheimer's disease.
- Higher level of certain fatty acid associated with lower dementia risk
Individuals who have higher levels of a fatty acid known as docosahexaenoic acid (DHA) in their blood may have a significantly lower risk of developing dementia and Alzheimer's disease.
- Higher level of certain fatty acid associated with lower dementia risk
Individuals who have higher levels of a fatty acid known as docosahexaenoic acid (DHA) in their blood may have a significantly lower risk of developing dementia and Alzheimer's disease.
- Higher level of certain fatty acid associated with lower dementia risk
Individuals who have higher levels of a fatty acid known as docosahexaenoic acid (DHA) in their blood may have a significantly lower risk of developing dementia and Alzheimer's disease.
- Higher level of certain fatty acid associated with lower dementia risk
Individuals who have higher levels of a fatty acid known as docosahexaenoic acid (DHA) in their blood may have a significantly lower risk of developing dementia and Alzheimer's disease.
- Higher level of certain fatty acid associated with lower dementia risk
Individuals who have higher levels of a fatty acid known as docosahexaenoic acid (DHA) in their blood may have a significantly lower risk of developing dementia and Alzheimer's disease.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- Pine Tree Bark Reduces Side Effects in Hypertensive Patients
Study published in the October journal of Clinical and Applied Thrombosis/Hemostasis shows Pycnogenol®, the bark of the French maritime pine tree reduced edema, a typical side-effect of antihypertensive medications, by 36 percent in the patients taking these medications.
- Pine Tree Bark Reduces Side Effects in Hypertensive Patients
Study published in the October journal of Clinical and Applied Thrombosis/Hemostasis shows Pycnogenol®, the bark of the French maritime pine tree reduced edema, a typical side-effect of antihypertensive medications, by 36 percent in the patients taking these medications.
- ON Uses All-Natural Vegetarian Approved Vcaps®
Optimum Nutrition (ON) is now using Vegetarian Society Approved Vcaps® to make a pair of diet products as well as the company’s popular gender specific multivitamin.
- ON Uses All-Natural Vegetarian Approved Vcaps®
Optimum Nutrition (ON) is now using Vegetarian Society Approved Vcaps® to make a pair of diet products as well as the company’s popular gender specific multivitamin.
- Eco Lips Highlights Co-branded Products at This Year’s Natural Products Expo West in Anaheim
Eco Lips highlights exciting new products at booth #4225 during Natural Products Expo West in Anaheim to be held March 12-14.
- Eco Lips Highlights Co-branded Products at This Year’s Natural Products Expo West in Anaheim
Eco Lips highlights exciting new products at booth #4225 during Natural Products Expo West in Anaheim to be held March 12-14.
- Eco Lips Highlights Co-branded Products at This Year’s Natural Products Expo West in Anaheim
Eco Lips highlights exciting new products at booth #4225 during Natural Products Expo West in Anaheim to be held March 12-14.
- Soaring Growth of Healthy and Nutritional Bars to €1.4 Billion
The market for healthy & nutritional bars is soaring, despite the economic recession. European Snack Bars sales have seen strong growth in 2009 with growth rate of 5% to €1.4 Billion.
- Soaring Growth of Healthy and Nutritional Bars to €1.4 Billion
The market for healthy & nutritional bars is soaring, despite the economic recession. European Snack Bars sales have seen strong growth in 2009 with growth rate of 5% to €1.4 Billion.
- Soaring Growth of Healthy and Nutritional Bars to €1.4 Billion
The market for healthy & nutritional bars is soaring, despite the economic recession. European Snack Bars sales have seen strong growth in 2009 with growth rate of 5% to €1.4 Billion.
- Soaring Growth of Healthy and Nutritional Bars to €1.4 Billion
The market for healthy & nutritional bars is soaring, despite the economic recession. European Snack Bars sales have seen strong growth in 2009 with growth rate of 5% to €1.4 Billion.
- Soaring Growth of Healthy and Nutritional Bars to €1.4 Billion
The market for healthy & nutritional bars is soaring, despite the economic recession. European Snack Bars sales have seen strong growth in 2009 with growth rate of 5% to €1.4 Billion.
- Soaring Growth of Healthy and Nutritional Bars to €1.4 Billion
The market for healthy & nutritional bars is soaring, despite the economic recession. European Snack Bars sales have seen strong growth in 2009 with growth rate of 5% to €1.4 Billion.
- Soaring Growth of Healthy and Nutritional Bars to €1.4 Billion
The market for healthy & nutritional bars is soaring, despite the economic recession. European Snack Bars sales have seen strong growth in 2009 with growth rate of 5% to €1.4 Billion.
- National Enzyme Company Names Shorey Account Executive
National Enzyme Company introduces Mark Shorey as Account Executive for the Retail Natural Health market channel.
- National Enzyme Company Names Shorey Account Executive
National Enzyme Company introduces Mark Shorey as Account Executive for the Retail Natural Health market channel.
- National Enzyme Company Names Shorey Account Executive
National Enzyme Company introduces Mark Shorey as Account Executive for the Retail Natural Health market channel.
- National Enzyme Company Names Shorey Account Executive
National Enzyme Company introduces Mark Shorey as Account Executive for the Retail Natural Health market channel.
- National Enzyme Company Names Shorey Account Executive
National Enzyme Company introduces Mark Shorey as Account Executive for the Retail Natural Health market channel.
- National Enzyme Company Names Shorey Account Executive
National Enzyme Company introduces Mark Shorey as Account Executive for the Retail Natural Health market channel.
- National Enzyme Company Names Shorey Account Executive
National Enzyme Company introduces Mark Shorey as Account Executive for the Retail Natural Health market channel.
- SunOpta Announces Fourth Quarter and Fiscal 2009 Results
SunOpta Inc. has announced FY09 Q4 results, reporting revenues of $245.5 million versus revenues of $245.0 million for the fourth quarter of 2008.
- SunOpta Announces Fourth Quarter and Fiscal 2009 Results
SunOpta Inc. has announced FY09 Q4 results, reporting revenues of $245.5 million versus revenues of $245.0 million for the fourth quarter of 2008.
- SunOpta Announces Fourth Quarter and Fiscal 2009 Results
SunOpta Inc. has announced FY09 Q4 results, reporting revenues of $245.5 million versus revenues of $245.0 million for the fourth quarter of 2008.
- SunOpta Announces Fourth Quarter and Fiscal 2009 Results
SunOpta Inc. has announced FY09 Q4 results, reporting revenues of $245.5 million versus revenues of $245.0 million for the fourth quarter of 2008.
- SunOpta Announces Fourth Quarter and Fiscal 2009 Results
SunOpta Inc. has announced FY09 Q4 results, reporting revenues of $245.5 million versus revenues of $245.0 million for the fourth quarter of 2008.
- Coromega(R) Sweetens Adult Omega-3 Supplement Line
Coromega(R) has unveiled Coromega Omega3 + Vitamin D, a squeeze supplement that provides a daily dose of omega-3s with added vitamin D3, and Coromega Omega3 Fruit Gummies, a high-DHA chewable gummy supplement for the kid in everyone.
- Coromega(R) Sweetens Adult Omega-3 Supplement Line
Coromega(R) has unveiled Coromega Omega3 + Vitamin D, a squeeze supplement that provides a daily dose of omega-3s with added vitamin D3, and Coromega Omega3 Fruit Gummies, a high-DHA chewable gummy supplement for the kid in everyone.
- Coromega(R) Sweetens Adult Omega-3 Supplement Line
Coromega(R) has unveiled Coromega Omega3 + Vitamin D, a squeeze supplement that provides a daily dose of omega-3s with added vitamin D3, and Coromega Omega3 Fruit Gummies, a high-DHA chewable gummy supplement for the kid in everyone.
- Coromega(R) Sweetens Adult Omega-3 Supplement Line
Coromega(R) has unveiled Coromega Omega3 + Vitamin D, a squeeze supplement that provides a daily dose of omega-3s with added vitamin D3, and Coromega Omega3 Fruit Gummies, a high-DHA chewable gummy supplement for the kid in everyone.
- Coromega(R) Sweetens Adult Omega-3 Supplement Line
Coromega(R) has unveiled Coromega Omega3 + Vitamin D, a squeeze supplement that provides a daily dose of omega-3s with added vitamin D3, and Coromega Omega3 Fruit Gummies, a high-DHA chewable gummy supplement for the kid in everyone.
- Coromega(R) Sweetens Adult Omega-3 Supplement Line
Coromega(R) has unveiled Coromega Omega3 + Vitamin D, a squeeze supplement that provides a daily dose of omega-3s with added vitamin D3, and Coromega Omega3 Fruit Gummies, a high-DHA chewable gummy supplement for the kid in everyone.
- Coromega(R) Sweetens Adult Omega-3 Supplement Line
Coromega(R) has unveiled Coromega Omega3 + Vitamin D, a squeeze supplement that provides a daily dose of omega-3s with added vitamin D3, and Coromega Omega3 Fruit Gummies, a high-DHA chewable gummy supplement for the kid in everyone.
- Scientific Food Solutions Signs Deal with Nutritional Impact Corp. for FAST-C™ in Soft Gels
Scientific Food Solutions (SFS) and Nutritional Impact Corporation (NIC) have signed a trademark license and material supply agreement for NIC to provide FAST-C™ in a soft gel delivery system to both the US and Canadian markets.
- Scientific Food Solutions Signs Deal with Nutritional Impact Corp. for FAST-C™ in Soft Gels
Scientific Food Solutions (SFS) and Nutritional Impact Corporation (NIC) have signed a trademark license and material supply agreement for NIC to provide FAST-C™ in a soft gel delivery system to both the US and Canadian markets.
- Scientific Food Solutions Signs Deal with Nutritional Impact Corp. for FAST-C™ in Soft Gels
Scientific Food Solutions (SFS) and Nutritional Impact Corporation (NIC) have signed a trademark license and material supply agreement for NIC to provide FAST-C™ in a soft gel delivery system to both the US and Canadian markets.
- Scientific Food Solutions Signs Deal with Nutritional Impact Corp. for FAST-C™ in Soft Gels
Scientific Food Solutions (SFS) and Nutritional Impact Corporation (NIC) have signed a trademark license and material supply agreement for NIC to provide FAST-C™ in a soft gel delivery system to both the US and Canadian markets.
|
Mount Laurel, NJ, September 25, 2006 - Fuji Health Science, Inc. (www.fujihealthscience.com), an American subsidiary of Fuji Chemical Industry Co., Ltd., Toyama, Japan announced today the publication of the ninth (9th) clinical study on AstaReal® astaxanthin for the reduction of asthenopia (eye fatigue). The effects of astaxanthin on eyestrain induced by accommodative dysfunction were investigated at the University of Occupational and Environmental Health, Department of Ophthalmology, Japan. Results showed a significant improvement in the astaxanthin supplemented group over the placebo group.
Dr. Vincent Wood, international marketing manager of Fuji Chemical explains, "This study is significant in that it targets prevention of eye fatigue as opposed to treatment.... In addition, this eye study includes a cross-over method which further substantiates astaxanthin’s properties in the prevention and treatment of eye fatigue."
This study is the ninth in a series of human clinicals performed with AstaReal astaxanthin showing efficacy for this growing health concern. In the age of increasing use of screen based equipment and entertainment, asthenopia is experienced by a growing number of people.
According to Charles DePrince, president of Fuji Health Science, "I see this study area for astaxanthin as representing an opportunity for the nutritional industry. Longer term issues such as AMD have been addressed by the industry as a whole, however, the more immediate and chronic issue of eye fatigue has been ignored. I believe the opportunity exists to broaden the eye care market."
Other areas of study on astaxanthin that Fuji is actively pursuing include cardiovascular, weight management, diabetes and metabolic syndrome. Fuji Chemical also holds seven patents for astaxanthin in the human application areas of inflammation, muscle endurance, immune system, dyspepsia, mastitis, fertility and H-pylori, as well as numerous pending patents. Fuji is the leading producer of natural astaxanthin for human nutritional use in the world with state of the art cultivation and production facilities in Maui, Hawaii and Gustavsberg, Sweden. Fuji’s astaxanthin products, AstaReal and AstaCarox, are approved for use in nutritional supplementation in the U.S., Europe, and Japan, as well as other markets worldwide.
- END - |